WHY PARTNER

The cell and gene therapy raw materials community are seeking solutions to address some of their long-lasting challenges surrounding sourcing, manufacturing and quality assurance of their raw materials.

The inaugural Raw Materials for Cell & Gene Therapy Summit is uniting Cell and Gene Therapy Drug Developers, Coordinating Bodies, Single-Use Technology Suppliers, Raw and Starting Material Suppliers and CRO’s to address the complexity in sourcing, quality testing, manufacturing, and adhering to multifaceted regulatory requirements to develop high-quality and cost-effective therapies for patients.

Top 3 Reasons to Partner:

Benefit From Market Intelligence

Hear how and where biopharma is searching for services and solutions to facilitate their efforts to source high-quality grade raw materials in line with regulatory expectations and match your premium services accordingly

Showcase your World-Class Solutions

Benefit from pre and post-conference exposure to our leading raw materials community to differentiate your services from your competitors and increase market share through unique branding formats

Forge Valuable Commercial Collaborations

With an all-encompassing room full of cell and gene raw material decision makers, meet prospective clients during speed networking breaks and informal networking opportunities throughout the full course of the conference

Who Will You Meet?

raw materials summit attendees
regulatory, cell and gene therapy

Innovation Partner - Agilent

www.agilent.com

regulatory, cell and gene therapy

Event Partner - Akron Bio

www.akronbiotech.com

Companies from our Expert Speaker Faculty Include:

raw materials summit, cell and gene therapy

Interested in partnering?
Get in touch below to to Benefit from Market Intelligence, Showcase Your World-Class Solutions and Forge Valuable Commercial Collaborations.

“I have not seen a conference or a forum specific to raw materials. This will definitely help companies to interact and gain some exposure to regulatory expectations around raw materials and single-use systems. This will ensure that they are prepared when their product is ready for commercialization” 

Asif Mahmood, Technical Director- Raw Materials, Bristol Myers Squibb

“Raw materials and material qualification is an emerging filed and knowledge sharing is key in the overall success of the cell and gene therapy space.  A lot of suppliers cannot support the needs of the cell and gene therapy raw material quality attributes and establishing a base line for everyone to be on the same page is the beginning” 

Sona Bairamian, Director- Materials Science, Atara Biotherapeutics